Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NACho: Neo-Adjuvant Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer
NCT07224022Phase 2Not yet recruiting
- Sponsor
- John Strickler
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
01
Overview
A Phase 2 trial of cemiplimab, fianlimab in colon cancer, sponsored by John Strickler. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
cemiplimabfianlimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT07224022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224022.